Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
This content is for educational purposes only and is not medical advice
-Six months of needle therapy, Roche/Alnylam's new SiRNA antihypertensive drug is planned to be included in breakthrough therapies On June 2, 2026, the Center for Drug Evaluation (CDE) of the National Medical Products Administration announced that Roche's Zilebesiran is intended to be included as a breakthrough therapy for adult hypertensive patients with cardiovascular disease or high risk of cardiovascular disease, in order to reduce the risk of cardiovascular death, non fatal myocardial infarction, non fatal stroke, and heart failure events (hospitalization or emergency treatment for heart failure)
Timing: Take with plenty of water, at least 30 minutes before or after other supplements to prevent interference with absorption
Call the member services number on the back of your insurance card
Learn more on our protein and weight loss page
US$ 25.64
US$ 24.60
US$ 20.91
US$ 23.88
US$ 25.65
US$ 24.64
